Parkinson's Disease Psychosis (DBCOND0037331)

Identifiers

Synonyms

Parkinson Disease Psychosis / Parkinson's disease psychosis

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Pimavanserin	A second generation atypical antipsychotic used for the treatment of hallucinations and delusions caused by Parkinson's Disease.	5-hydroxytryptamine receptor 2Atarget 5-hydroxytryptamine receptor 2Ctarget Sigma non-opioid intracellular receptor 1target Cytochrome P450 3A4enzyme Cytochrome P450 3A5enzyme Cytochrome P450 2J2enzyme Cytochrome P450 2D6enzyme

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT06068465	A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis	Pimavanserin	treatment	3	recruiting
NCT01174004	A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis	Pimavanserin	treatment	3	completed
NCT00477672	A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis	Pimavanserin	treatment	3	completed
NCT00550238	A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis	Pimavanserin	treatment	3	completed
NCT01518309	An Open-label Safety Study of Pimavanserin in Parkinson's Disease Patients	Pimavanserin	treatment	2	completed
NCT05590637	Comparing Antipsychotic Medications in LBD Over Time	Pimavanserin Quetiapine	treatment	4	recruiting
NCT04373317	Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis	Pimavanserin Quetiapine	treatment	4	recruiting
NCT02762591	Expanded Access of Pimavanserin for Patients With PD Psychosis	Pimavanserin	Not Available	Not Available	approved_for_marketing
NCT00658567	A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis	Pimavanserin	treatment	3	completed
NCT05824728	Clinical Trial Evaluating the Efficacy and Safety of AGB101 for Treatment of Parkinson's Disease Related Psychosis	Levetiracetam	treatment	2	recruiting
NCT06450184	Bioequivalence Study of Pimavanserin 34 mg Capsule	Pimavanserin	other	1	completed
NCT04579887	Presence Hallucination in Parkinson's Disease	No drug interventions	basic_science	Not Available	unknown_status
NCT05240339	Characterization and Progression of Minor Phenomena in Parkinson's Disease (PD)	No drug interventions	Not Available	Not Available	completed
NCT04292223	Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis	Pimavanserin	treatment	4	completed
NCT03661125	SRC Inhibition as a Potential Target for Parkinson's Disease Psychosis	Saracatinib	basic_science	0	unknown_status
NCT04592965	Hallucinations in Parkinson's Disease	No drug interventions	basic_science	Not Available	unknown_status
NCT05344365	A Study to Evaluate Iloperidone for the Treatment of Parkinson's Disease Psychosis	Iloperidone	treatment	2	withdrawn
NCT05995782	A Phase 1, SAD and MAD Study to Evaluate the Safety and Tolerability of FB418	No drug interventions	treatment	1	not_yet_recruiting
NCT03152292	The INSYTE (Management of Parkinson's Disease Psychosis in Actual Practice) Study	No drug interventions	Not Available	Not Available	terminated
NCT02969369	A Study to Evaluate the Efficacy, Safety and Tolerability of SEP-363856 in Subjects With Parkinson's Disease Psychosis	SEP-363856	treatment	2	completed
NCT05357612	Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases	Pimavanserin	basic_science	4	recruiting